CP2C-TARGETING PEPTIDE-BASED ANTICANCER AGENT
The presented invention relates to a CP2c-targeting peptide-based anticancer agent. A CP2c-targeting peptide according to the presented invention binds to transcription factor CP2c to inhibit the formation of transcription factor CP2c complexes (CP2c homotetramer and CP2c/CP2b/PIAS1 heterohexamer), thereby inducing cancer cell-specific cell death. A fatty acid is bound to the peptide to ensure stability enabling long-term sustenance in vivo..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Europäisches Patentamt - (2022) vom: 26. Mai Zur Gesamtaufnahme - year:2022 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
KIM CHUL GEUN [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2022-05-26, Last update posted on www.tib.eu: 2023-06-14, Last updated: 2023-06-23 |
|---|
| Patentnummer: |
US2022160888 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA01544113X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA01544113X | ||
| 003 | DE-627 | ||
| 005 | 20230623180519.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230216s2022 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA01544113X | ||
| 035 | |a (EPA)US2022160888 | ||
| 035 | |a (EPA)72667243 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a KIM CHUL GEUN |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a CP2C-TARGETING PEPTIDE-BASED ANTICANCER AGENT |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2022-05-26, Last update posted on www.tib.eu: 2023-06-14, Last updated: 2023-06-23 | ||
| 520 | |a The presented invention relates to a CP2c-targeting peptide-based anticancer agent. A CP2c-targeting peptide according to the presented invention binds to transcription factor CP2c to inhibit the formation of transcription factor CP2c complexes (CP2c homotetramer and CP2c/CP2b/PIAS1 heterohexamer), thereby inducing cancer cell-specific cell death. A fatty acid is bound to the peptide to ensure stability enabling long-term sustenance in vivo. | ||
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a KIM MIN YOUNG |4 aut | |
| 700 | 0 | |a KIM CHAN GIL |4 aut | |
| 700 | 0 | |a SON SEUNG HAN |4 aut | |
| 700 | 0 | |a KIM JI SOOK |4 aut | |
| 700 | 0 | |a CHOI SUNG WOO |4 aut | |
| 700 | 0 | |a LEE SEOL EUI |4 aut | |
| 700 | 0 | |a CHUNG MIN SUNG |4 aut | |
| 700 | 0 | |a PARK DONG SUN |4 aut | |
| 700 | 0 | |a LEE SANG WON |4 aut | |
| 700 | 0 | |a JEONG JAE MIN |4 aut | |
| 700 | 0 | |a CHOI DONG HO |4 aut | |
| 700 | 0 | |a JANG KI SEOK |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2022) vom: 26. Mai |
| 773 | 1 | 8 | |g year:2022 |g day:26 |g month:05 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/72667243/publication/US2022160888A1?q=US2022160888 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2022 |b 26 |c 05 |
| 951 | |a AR | ||
| 952 | |j 2022 |b 26 |c 05 | ||